Month: January 2021

In accordance with the Remuneration Policy approved at the annual general meeting on 17 December 2019, Ambu A/S has today launched a long-term incentive plan for the Executive Board. In addition, 186 key employees in the global organisation are enrolled in the plan on similar terms. In the plan, the Executive Board receives a total of up to 66,410 Performance Share Units (PSUs) while key employees receive a total of up to 139.266 PSUs. Each PSU may at vesting – on 1 January 2024 – be converted to one B share in Ambu A/S subject to the terms of the program.The plan covers the financial year 2020/21, and the PSUs will be allocated based on how targets for organic revenue growth for 2020/21 are achieved. Final allocation will be within 0-100% of the grant. The aggregate fair market value of the total allocation at the time of grant equals...

Detroit, Jan. 29, 2021 (GLOBE NEWSWIRE) — DETROIT, Jan. 29, 2021 – Today, DTE announced that it will accelerate its commitment to support and empower people with disabilities in the workforce by joining The Valuable 500, a coalition of the world’s largest companies dedicated to promoting disability inclusion through business leadership and opportunity.“At DTE, we understand that all people thrive and succeed when they feel included, welcome and safe,” said Jerry Norcia, president and CEO, DTE Energy. “We’re proud and excited to join with others to form The Valuable 500 as we continue to drive inclusion and empower people living with disabilities with support and opportunities in our company and our communities.”As part of its pledge to The Valuable 500, DTE will expand its partnership with Project Search, a...

TORONTO, Jan. 29, 2021 (GLOBE NEWSWIRE) — MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE:MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction, distillation and derivative products, is pleased to announce Greg Hunter will join MediPharm Labs as Chief Financial Officer (CFO), effective February 8, 2021.Greg Hunter brings over 20 years of experience as a business executive holding various senior finance and leadership roles across multiple industries including healthcare distribution, telecommunications, pharmaceuticals, biotechnology, medical device and consumer packaged goods. Greg also brings a track record and deep expertise in capital management, audit, compliance, tax, treasury, ERP, manufacturing, contract management and pricing strategy.“As...

VANCOUVER, British Columbia, Jan. 29, 2021 (GLOBE NEWSWIRE) — Choom™ (CSE: CHOO; OTCQB: CHOOF), one of Canada’s leading recreational cannabis retailers, is pleased to announce the opening of its latest retail location in the Yaletown neighborhood of Vancouver, B.C. (1391 Richards Street, Vancouver V6B 3G7). The brand currently has 15 locations operational across Alberta, Ontario, and B.C, with ambitious expansion plans through 2024.“It’s an exciting start to 2021 for Choom, we are seeing the expansion of our brand in our hometown of Vancouver,” said Corey Gillon, CEO of Choom. “We continue to see the brand come to life, through the tireless efforts of our team. Choom is staying true to our vision; providing a best-in-class retail cannabis experience to every client, in every market we serve.”The brand continues to build its community...

NEW YORK, Jan. 29, 2021 (GLOBE NEWSWIRE) — via InvestorWire — SRAX (NASDAQ: SRAX) today announces its placement in an editorial published by NetworkNewsWire (“NNW”), one of 50+ trusted brands within the InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities.To view the full publication, “Trade Volume Explodes as Retail Traders Make Their Mark,” please visit: https://nnw.fm/bEaWXEvidence points to increased retail trading as the primary impetus in the record-setting increase in volume with much of the real volume increase coming from little-known names in the small cap market. Electronic brokers are hitting new highs as investment markets become more retail driven, and independent investors are making marks in their own portfolios. This new dynamic puts new pressure...

NEW YORK, Jan. 29, 2021 (GLOBE NEWSWIRE) — WisdomTree Investments, Inc. (NASDAQ: WETF) today reported financial results for the fourth quarter of 2020.($13.5) million net loss ($9.21million net income, as adjusted), see “Non-GAAP Financial Measurements” for additional information.$22.4 million of non-cash charges, associated with the revaluation of deferred consideration – gold payments.$67.4 billion of ending AUM, an increase of 11.0% arising from market appreciation and net inflows.$881 million of net inflows, driven by inflows into our emerging markets equity and U.S. equity products, partly offset by outflows from our fixed income, commodity, international developed market equity and leveraged & inverse products.0.41% average global advisory fee, a decrease of 1 basis point due to AUM mix shift.$67.1 million of operating...

25th consecutive year of record net revenues of $3.8 billion, an increase of 12.4% compared with 2019.Quarterly record net revenues of $1.1 billion, an increase of 20.0% over the third quarter of 2020.Record quarterly net income available to common shareholders of $180.8 million, or $1.55 per diluted common share.(1)Record non-GAAP net income available to common shareholders of $195.1 million, or $1.67 per diluted common share.(1)Record client assets of $357.4 billion, increased 8.5% compared with the year-ago quarter.Annualized return on average tangible common shareholders’ equity(2) was 30.8%.Non-GAAP annualized return on average tangible common shareholders’ equity(2) was 33.3%.Increasing quarterly dividend by approximately 32% to $0.15 per common share starting in first quarter of 2021.ST. LOUIS, Jan. 29, 2021 (GLOBE NEWSWIRE) —...

Highly potent in vivo anti-inflammatory activity demonstrated for novel small molecule NLRP3 inhibitorsHigh-affinity antibodies against extracellular components of the inflammasome pathway show inhibition of target inflammatory responsesLAUSANNE, Switzerland, Jan. 29, 2021 (GLOBE NEWSWIRE) — AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced recent advancements in its small molecule- and antibody-based therapeutic programs targeting the (NOD)-like receptor protein 3 (NLRP3) inflammasome, a multi-protein complex that activates downstream inflammatory pathways leading to neuronal damage. The inflammasome is a highly valued therapeutic target implicated in a wide range of neurodegenerative disorders including Alzheimer’s disease...

– Tandem WiFi 6E BAW Coexistence RF Filters to Be Used in New MU-MIMO Router Product –– Customer’s Product Expected to Enter Production in Second Half of CY2021 –– XBAW Filter Solution Offers Superior Coexistence Enabling Use of Entire New WiFi 6E Frequency Spectrum –Charlotte, N.C., Jan. 29, 2021 (GLOBE NEWSWIRE) — Akoustis Technologies, Inc. (NASDAQ: AKTS) (“Akoustis” or the “Company”), an integrated device manufacturer (IDM) of patented bulk acoustic wave (BAW) high-band RF filters for mobile and other wireless applications, announced today that it has received a volume order for its 5.5 GHz and 6.5 GHz XBAW® WiFi 6E filter solutions from a new tier-1 customer.The 5.5 GHz filter module covers the entire 5.1 to 5.8 GHz spectrum of the WiFi 6E standard, while the 6.5 GHz filter module covers the entire 5.9 to 7.1 GHz spectrum....

BOSTON and LONDON, Jan. 29, 2021 (GLOBE NEWSWIRE) — Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced the appointment of Braden Parker to the role of Chief Commercial Officer (CCO). In this capacity, Mr. Parker will oversee all aspects of commercial strategy, planning and operations for the company. Mr. Parker is a seasoned commercial leader with more than 20 years of experience in the healthcare and biotech industry, including deep rare disease and gene therapy experience. Mr. Parker’s previous positions include commercial leadership roles at Celgene, NPS Pharma (Shire) and PTC Therapeutics, where he led the company’s first U.S. product launch in Duchenne muscular dystrophy and oversaw the strategic planning for their gene therapy business. Most recently, Mr. Parker served as Orchard’s senior vice...